Study findings further support the use of SGLT2 inhibitors in a broad range of patients with type 2 diabetes, according to investigators.
A phase 3 trial to evaluate dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a potential treatment for patients hospitalized with coronavirus disease 2019.
The risks for major events increased with the degree of albuminuria among patients with type 2 diabetes mellitus and no overt cardiovascular disease.
Decreased rates of hyperfiltration, elevated UAE seen among surgically treated obese teens with T2DM.
In a 52-week study, daily treatment with patiromer maintained normokalemia in patients, regardless of age.
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.
Odds of diabetic kidney disease higher in obese teens receiving medical therapy versus bariatric surgery for T2DM
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
Sweden’s lower HbA1c target values not linked to further organ protection